XLT Biopharmaceuticals acquired 85% of NeuroNOS, enhancing its presence in autism drug development. NeuroNOS's research, led by Nobel laureates, focuses on targeting nitric oxide imbalances, addressing a critical gap in available treatments. The deal could transform XLT's portfolio amid rising federal support for autism research.